Nuevo número de la revista AIDS
Publicada AIDS, volumen 25, número 18, noviembre 28 del 2011. Los usuarios de la red sld.cu tiene acceso al texto completo de esta publicación a través de Hinari. Algunos de sus titulares son:
Challenges and opportunities for hepatitis C drug development in HIV–hepatitis C virus-co-infected patients
Regulation of the susceptibility of HIV-1 to a neutralizing antibody KD-247 by nonepitope mutations distant from its epitope
Rising HIV-1 viral load set point at a population level coincides with a fading impact of host genetic factors on HIV-1 control
Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir
Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance
Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase
Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results
Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata
Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection
Early antiretroviral therapy in HIV-1-infected infants, 1996–2008: treatment response and duration of first-line regimens
Lessons learned in the deployment of a HIV counseling and testing management information system on a new project
Modeling the impact on the HIV epidemic of treating discordant couples with antiretrovirals to prevent transmission
Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis
Association of osteonecrosis and peripheral neuropathy in HIV-1-infected patients: possible roles of nerve growth factor and vascular endothelial growth factor
Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient
The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis
